4 stories mentioning NSE:AJANTPHARMUpdated 136d ago
Every FINWIRES story that references NSE:AJANTPHARM, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has an average rating of buy and mean price target of 3,268.38 Indian rupees, according to analysts polled by FactSet.
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) recorded a rise in its consolidated net profit to 2.67 billion Indian rupees in the fiscal fourth quarter ended March 31 from 2.25 billion rupees a year ago.Earnings per share climbed to 21.34 rupees from 18 rupees a year earlier, according to a Tuesday filing by the pharmaceutical company.Revenue from operations in fiscal Q4 also increased to 14.2 billion rupees from 11.7 billion rupees a year earlier, the filing said.
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has received five observations from the US FDA concluded an inspection at our manufacturing facility at Paithan in Maharashtra, India, according to a filing to the Indian stock exchanges.The regulator inspected the facility from April 13 to 21 and closed with the issuance of Form-483 with five observations.The company said it will respond to the U.S. FDA within the stipulated timeline.The company's shares were down nearly 1% in recent trade.
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) has an average rating of buy and mean price target of 3,238.25 Indian rupees, according to analysts polled by FactSet.
